Le rein, un nouvel organe cible des hypoglycémiants

Kidney plays a important role in glucose homeostasis. Inhibiting sodium - glucose cotransporters (SGLTs), which have a key role in the reabsorption of glucose in the kidney, has been proposed as a novel therapeutic strategy for diabetes. Genetic mutations in the kidney-specific SGLT2 isoform that result in benign renal glycosuria, as well as preclinical and clinical studies with SGLT2 inhibitors in type 2 diabetes, support the potential of this approach. These investigations indicate that elevating renal glucose excretion by partially blocking SGLT2 can reduce plasma glucose levels, as well as decrease weight. Apart a small increase in genital infections, safety and tolerability seem to be good. Although more data from ongoing clinical trials of these agents are needed to more fully assess safety, current results suggest a favourable benefits/risks profile.